Correlation Between Blueprint Medicines and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both Blueprint Medicines and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Blueprint Medicines and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Blueprint Medicines Corp and Inhibikase Therapeutics, you can compare the effects of market volatilities on Blueprint Medicines and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Blueprint Medicines with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Blueprint Medicines and Inhibikase Therapeutics.
Diversification Opportunities for Blueprint Medicines and Inhibikase Therapeutics
0.37 | Correlation Coefficient |
Weak diversification
The 3 months correlation between Blueprint and Inhibikase is 0.37. Overlapping area represents the amount of risk that can be diversified away by holding Blueprint Medicines Corp and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Blueprint Medicines is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Blueprint Medicines Corp are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Blueprint Medicines i.e., Blueprint Medicines and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between Blueprint Medicines and Inhibikase Therapeutics
Given the investment horizon of 90 days Blueprint Medicines is expected to generate 1.59 times less return on investment than Inhibikase Therapeutics. But when comparing it to its historical volatility, Blueprint Medicines Corp is 2.62 times less risky than Inhibikase Therapeutics. It trades about 0.12 of its potential returns per unit of risk. Inhibikase Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest 261.00 in Inhibikase Therapeutics on September 4, 2024 and sell it today you would earn a total of 15.00 from holding Inhibikase Therapeutics or generate 5.75% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Blueprint Medicines Corp vs. Inhibikase Therapeutics
Performance |
| Timeline |
| Blueprint Medicines Corp |
| Inhibikase Therapeutics |
Blueprint Medicines and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Blueprint Medicines and Inhibikase Therapeutics
The main advantage of trading using opposite Blueprint Medicines and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Blueprint Medicines position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.| Blueprint Medicines vs. Terns Pharmaceuticals | Blueprint Medicines vs. Amylyx Pharmaceuticals | Blueprint Medicines vs. Acumen Pharmaceuticals | Blueprint Medicines vs. Inozyme Pharma |
| Inhibikase Therapeutics vs. Candel Therapeutics | Inhibikase Therapeutics vs. Cingulate Warrants | Inhibikase Therapeutics vs. Unicycive Therapeutics | Inhibikase Therapeutics vs. Cardio Diagnostics Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Other Complementary Tools
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |